Public companies, decoded straight from their own filings.
Every article on Analysis10k starts with a 10-K, a 10-Q, or an earnings call transcript — never a headline. We publish three angles per company: what it does, how its story has changed, and what its stock price is betting on.
Latest posts
View all posts →Eli Lilly (LLY): What This Company Actually Does
A plain-English read of Eli Lilly's business model, built directly from its SEC filings — no hype, just where the money comes from.
2026-09-28The StoryEli Lilly's Last Three Years: A Company That Couldn't Keep Up With Its Own Success
How Mounjaro and Zepbound demand kept outrunning Eli Lilly's own guidance — and how the two moments that looked like trouble both turned into launching pads for the next raise.
2026-09-28Reverse DCFWhat LLY's Stock Price Is Really Betting On
Reverse-engineering the growth rate Eli Lilly's current share price already assumes — and why the answer swings wildly depending on which year's cash flow you use as a baseline.
2026-09-28Company SnapshotAbbVie (ABBV): What This Company Actually Does
A plain-English read of AbbVie's business model, built directly from its SEC filings — no hype, just where the money comes from.
2026-09-27The StoryAbbVie's Last Three Years: 'Raising Guidance' While the Number Keeps Falling
How a CEO transition and a buying spree turned AbbVie's own guidance language into a puzzle worth decoding every quarter.
2026-09-27Reverse DCFWhat ABBV's Stock Price Is Really Betting On
Reverse-engineering the growth rate AbbVie's current share price already assumes — and checking it against five years of shrinking free cash flow.
2026-09-27